By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%).

Characteristics and treatment of Omicron variant of COVID-19.

The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike-protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by Sotrovimab.

Authors: Ospina-Tascon GA, Calderon-Tapia LE, Garcia AF, Zarama V, Vargas MP, Vaaron J PMID: 34874419 PMCID: PMC8652598 DOI: 10.1001/jama.2021.20714 Abstract Importance: The effect of high-flow oxygen therapy vs conventional oxygen therapy has not been established in the setting of severe COVID-19. Objective: To determine the effect of high-flow oxygen therapy through a nasal cannula compared [...]

Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Lopez-Miranda J PMID: 34862422 PMCID: PMC8642445 DOI: 10.1038/s41598-021-02701-5 Abstract COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival [...]

Authors: Miranda-Massari JR, Toro AP, Loh D, Rodriguez JR, Borges RM PMID: 34947872 PMCID: PMC8708699 DOI: 10.3390/life11121341 Abstract Currently available anti-viral drugs may be useful in reducing the viral load but are not providing the necessary physiological effects to reduce the SARS-CoV-2 complications efficiently. Treatments that provide better clinical outcomes are urgently needed. Vitamin C [...]

Jorge R Miranda-Massari, Alondra P Toro, Doris Loh, Jose R Rodriguez, Raul Morales Borges, Victor Marcial-Vega, Jose Olalde, Miguel J Berdiel, Neil H Riordan, Juan Manuel Martinez, Armando Gil, Michael J Gonzalez PMID: 34947872 PMCID: PMC8708699 DOI: 10.3390/life11121341 AbstractCurrently available anti-viral drugs may be useful in reducing the viral load but are not providing the [...]

Authors: Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Likic R PMID: 34719789 PMCID: PMC8653355 DOI: 10.1111/bcp.15126 Abstract Aims: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in three trials. The aim of this [...]

Authors: Kiprov DD, Herskowitz A, Kim D, Lieb M, Liu C, Watanabe E PMID: 35464182 PMCID: PMC9021669 DOI: 10.12688/f1000research.74534.2 Abstract Many patients with COVID-19 experience a range of debilitating symptoms months after being infected, a syndrome termed long-haul COVID. A 68-year-old male presented with lung opacity, fatigue, physical and cognitive weaknesses, loss of smell and [...]

Auhtors: Medini H, Zirmman A, Mishmar D PMID: 34812416 PMCID: PMC8599136 DOI: 10.1016/j.isci.2021.103471 Abstract Mitochondria are pivotal for bioenergetics, as well as in cellular response to viral infections. Nevertheless, their role in COVID-19 was largely overlooked. Here, we analyzed available bulk RNA-seq datasets from COVID-19 patients and corresponding healthy controls (three blood datasets, N = [...]